

**Product Name** : LNP023

**Synonyms** : LNP-023; LNP 023


**Cat No.** : M12510

**CAS Number** : 1644670-37-0

**Molecular Formula** : C<sub>25</sub>H<sub>30</sub>N<sub>2</sub>O<sub>4</sub>

**Formula Weight** : 422.53

**Chemical Name** : 4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic acid



**Description** : LNP023 (LNP-023) is a highly potent, reversible, selective inhibitor of factor B (IC<sub>50</sub>=10 nM), the proteolytically active component of the C3 and C5 convertases; shows direct, reversible, and high-affinity binding to human FB with K<sub>d</sub> of 7.9 nM in SPR assays, demonstrates potent inhibition of AP-induced MAC formation in 50% human serum with IC<sub>50</sub> of 0.13 μM; shows no inhibition of factor D (FD), as well as classical or lectin complement pathway activation (up to 100 μM), and no significant effects (up to 10 μM) in a broad assay panel of receptors, ion channels, kinases, and proteases; blocks zymosan-induced MAC formation membrane attack complex (MAC) with IC<sub>50</sub> of 0.15 μM, prevents KRN-induced arthritis in mice and is effective upon prophylactic and therapeutic dosing in an experimental model of membranous nephropathy in rats after oral administration; also prevents complement activation in sera from C3 glomerulopathy patients and the hemolysis of human PNH erythrocytes. Other Indication Phase 2 Clinical

**Pathway** : Immunology/Inflammation

**Target** : Complement System

**Receptor** : Complement System

**Solubility** : —

**SMILES** : O=C(O)C1=CC=C(C=C1)[C@H]2N(CC3=C(OC)C=C(C)C4=C3C=CN4)CC[C@H](COC)C2

**Storage** : (-20°C)

**Stability** : ≥ 2 years

**Reference** :

1. Schubart A, et al. Proc Natl Acad Sci U S A. 2019 Mar 29. pii: 201820892.